Nedaplatin in nasopharyngeal cancer: the rebirth of platinum salts?

Mené en Chine sur 402 patients atteints d'un carcinome rhino-pharyngé de stade II à IVB (âge : 18 à 65 ans), cet essai de phase III évalue, du point de vue de la survie sans progression à 2 ans, la non infériorité du nédaplatine par rapport au cisplatine dans le cadre d'une chimioradiothérapie concomitante

Résumé en anglais

During the past 20 years, three major advances have helped to substantially improve the prognosis of patients with nasopharyngeal carcinoma. First, the use of cisplatin-based concurrent chemoradiation,1 alone2 or with adjuvant3,4 or induction5,6 chemotherapy, has led to improved survival and disease control. Second, the advent of intensity-modulated radiotherapy has allowed treatment volumes to be adapted to the local and regional extension of disease, especially for patients with a posterior extension close to neurological structures, along with better protection of adjacent normal tissues.